SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for medical trials, immediately introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm creating therapies for neurodegenerative ailments. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration centered on remynd’s Part 2a medical trial of REM127, an investigational, first-generation small molecule remedy concentrating on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The examine enrolled a restricted variety of individuals and measured adjustments in AD biomarkers over a brief remedy window.
Unlearn supported the examine by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin skilled on knowledge from greater than 26,000 individuals throughout landmark AD datasets comparable to ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their medical and biomarker trajectories beneath commonplace care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering an extra layer of proof to assist interpret adjustments noticed within the handled inhabitants. This strategy is especially useful in early-phase research the place small pattern sizes restrict the power to attract conclusions utilizing conventional statistical strategies alone.
“It is a highly effective instance of how digital twins can assist unlock insights from small research,” mentioned Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to help smarter, sooner medical analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering strategy in direction of reaching symptomatic reduction and illness modification in Alzheimer’s. This can help our efforts to advance an optimized second-generation remedy,” mentioned Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for decoding biomarker traits over time—particularly in early-stage trials the place each knowledge level issues.”
For extra data, go to www.unlearn.ai or comply with us on LinkedIn and X/Twitter.
